| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/25/2005 | CN1620466A Cystine-knot fold protein |
| 05/25/2005 | CN1620461A 2-amino-propanol derivatives |
| 05/25/2005 | CN1620459A 稠合双环嘧啶衍生物 Fused bicyclic pyrimidine derivative |
| 05/25/2005 | CN1620457A Tetracyclic heterocompounds as estrogen receptor modulators |
| 05/25/2005 | CN1620455A Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| 05/25/2005 | CN1620454A Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 05/25/2005 | CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| 05/25/2005 | CN1620451A Benzhydryl derivatives |
| 05/25/2005 | CN1620447A Isochroman compounds for treatment of cns disorders |
| 05/25/2005 | CN1620440A Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| 05/25/2005 | CN1620438A 5, 6-diaryl-pyrazine-2-amide derivatives as CBI antagonists |
| 05/25/2005 | CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 05/25/2005 | CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors |
| 05/25/2005 | CN1620433A Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 05/25/2005 | CN1620431A (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| 05/25/2005 | CN1620424A Compounds for the treatment of inflammatory disorders |
| 05/25/2005 | CN1620420A Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 05/25/2005 | CN1620419A 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| 05/25/2005 | CN1620414A 维生素d类似物 Vitamin d analogues |
| 05/25/2005 | CN1620311A Therapeutic agent |
| 05/25/2005 | CN1620304A Prevention and treatment of oxidative stress disorders by glutathione and phase IIdetoxification enzymes |
| 05/25/2005 | CN1620301A Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 05/25/2005 | CN1620299A Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses |
| 05/25/2005 | CN1620290A Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| 05/25/2005 | CN1620281A Formulation & dosage form for the controlled delivery of therapeutic agents |
| 05/25/2005 | CN1618805A Nerve system development related protein and its coding sequence and use |
| 05/25/2005 | CN1618791A New synthesis method of alipirazole |
| 05/25/2005 | CN1618458A Novel dopaminergic neuron protective factor, and its application |
| 05/25/2005 | CN1618452A Sobering beverage made of Chinese herbal medicines, and its prepn. method |
| 05/25/2005 | CN1618435A Oral liquor for promoting-blood circulation and removing blood stasis contg. Radix astragali and ginseng |
| 05/25/2005 | CN1203070C Thrombin receptor antagonists |
| 05/25/2005 | CN1203069C Substituted piperidines, medicaments containing these compounds, and methods for production thereof |
| 05/25/2005 | CN1203066C (Methylsulfonyl) phenyl-2-(5H)-furanones as cos-2 inhibitors |
| 05/25/2005 | CN1203061C Substituted isoquinolines, its preparing process, medical composition and its use for preparing medicine |
| 05/25/2005 | CN1203060C Pyridine derivatives, its composition and use |
| 05/25/2005 | CN1203058C Piperidine derivatives and drugs containing these derivatives as active ingredient |
| 05/25/2005 | CN1203047C Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| 05/25/2005 | CN1202843C Narcotic medical composition, preparing process and use thereof |
| 05/25/2005 | CN1202826C Neuropathy remedies |
| 05/25/2005 | CN1202823C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack |
| 05/25/2005 | CN1202822C Nimodipine slow release capsule and its preparation method |
| 05/25/2005 | CN1202821C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (MIDDM) attack |
| 05/25/2005 | CN1202815C Delayed-action form of administration containing tramadol saccharinate |
| 05/24/2005 | US6897319 Therapeutic drugs for treating central nervous system disorders |
| 05/24/2005 | US6897318 Process for making substituted pyrazoles |
| 05/24/2005 | US6897310 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction |
| 05/24/2005 | US6897232 Activate soluble guanylate cyclase; for use treating cardiovascular disorders, erectile dysfunction, diabetes, and cirrhosis of the liver, kidney disorders, and learning disability |
| 05/24/2005 | US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole |
| 05/24/2005 | US6897226 NK-1 receptor active amine oxide prodrugs |
| 05/24/2005 | US6897219 Central nervous system diosrders; analgesics; antiinflammatory agents |
| 05/24/2005 | US6897218 Nitric oxide donors based on metallic centers |
| 05/24/2005 | US6897217 Central nervous system diosrders; Parkinson's disease; sedatives, antixiolytic agents, antiepileptic agents |
| 05/24/2005 | US6897216 Adenosine A2a receptor antagonists |
| 05/24/2005 | US6897212 Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones |
| 05/24/2005 | US6897206 Combinations for the treatment of inflammatory disorders |
| 05/24/2005 | US6897203 Polysaccharidic esters of retinoic acid |
| 05/24/2005 | US6896901 Controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin in mammals by administering pharmaceutically acceptable effective amount of gugulipid |
| 05/24/2005 | US6896886 Administering neurotoxins; analgesics; antisecretory agent |
| 05/24/2005 | CA2354237C A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd) |
| 05/24/2005 | CA2195615C A process for the manufacture of imidazodiazepine derivatives |
| 05/24/2005 | CA2170243C Novel therapeutic and dietetic uses of a brain phospholipid-based complex |
| 05/19/2005 | WO2005044291A1 Grape seed extract having neuronal cell-protecting activity and the composition comprising the same for prepenting and treating degenerative brain disease |
| 05/19/2005 | WO2005044093A2 Delta-9- the treatment of multiple sclerosis |
| 05/19/2005 | WO2005018545A3 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| 05/19/2005 | WO2005016898B1 Stable polymorph of bifeprunox mesilate |
| 05/19/2005 | WO2005016228A3 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 05/19/2005 | WO2005014576A8 Isoquinolinone derivative, process for producing the same and use thereof |
| 05/19/2005 | WO2004106934A3 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7) |
| 05/19/2005 | WO2004028540A9 Anti-neurodegenerative agents |
| 05/19/2005 | WO2003014703A3 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 05/19/2005 | WO2003009815A3 Compositions and methods for modulating blood-brain barrier transport |
| 05/19/2005 | WO2002069893A3 Treatment of neurological disease |
| 05/19/2005 | US20050108785 Using nuclear transplantation as tool in generating transgenic cells for treatment and prevention of liver, nervous system, cardiovascular and bone disorders; regenerative medicine |
| 05/19/2005 | US20050107611 For use as adenosine receptor ligands; immunostimulants; contraceptives |
| 05/19/2005 | US20050107601 Nucleotide sequences coding immunoglobulin fusion specific to heparan sulfate proteoglycans for use as diagnostic and therapeutic tool in treatment and prevention of neurodegenerative and cell proliferative disorders |
| 05/19/2005 | US20050107472 administering vitamin k derivatives for prophylaxis of neurodegenerative diseases associated with protein aggregation or neurofibrillary tangles |
| 05/19/2005 | US20050107460 N-heteroaryl-, naphthyl or azulenyl-substituted 1-azabicycloalkylcarboxamides; treatment and/or prophylaxis of impairments of perception, concentration, learning and/or memory |
| 05/19/2005 | US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors |
| 05/19/2005 | US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 05/19/2005 | US20050107455 Novel tricycloimidazoline derivatives method for production and use thereof as medicaments |
| 05/19/2005 | US20050107450 administering Peroxisome Proliferator Activated Receptors (PPAR-gamma) activators according to a dosage schedule which comprises a cycle of less than daily administration |
| 05/19/2005 | US20050107432 such as 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methylpiperidine, used for treating nervous system, neurodegenerative and/or psychological disorders |
| 05/19/2005 | US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 05/19/2005 | US20050107425 in mammals comprising administering alpha-7-nicotinic acetylcholine receptors (alpha-7-nAChR) agonists, and psychostimulants and/or monoamine reuptake inhibitors |
| 05/19/2005 | US20050107413 pyrimidine derivatives such as 4-Chloro-5,6-diphenyl-2-(trifluoromethyl)pyrimidine, used for the treatment of inflammation and immunological diseases |
| 05/19/2005 | US20050107411 Method for treating circadian rhythm disruptions |
| 05/19/2005 | US20050107410 Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
| 05/19/2005 | US20050107405 administering cyclic guanosine monophosphate phosphodiestarase (cGMP PDE5) inhibitors such as sildenafil salts, as analgesics or antispasmodic agents |
| 05/19/2005 | US20050107402 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
| 05/19/2005 | US20050107397 Sulfonamide derivatives as d3-receptor agonists |
| 05/19/2005 | US20050107390 i.e. 7-[(3R)-3-Amino-4-(3,4-difluorophenyl)butanoyl]-3-methyl-6-(phenylmethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine, dihydrochloride; antilipemic, antiobesity |
| 05/19/2005 | US20050107388 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain |
| 05/19/2005 | US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC |
| 05/19/2005 | US20050107380 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle |
| 05/19/2005 | US20050107379 antithrombolytic agents such as (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide, used for therapy of cardiovascular disorders |
| 05/19/2005 | US20050107375 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists |
| 05/19/2005 | US20050107356 synergistic effect; CB1 receptor antagonist is an azetidine compound of given formula such as 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine), and the dopaminergic agent is ropinirole for example |
| 05/19/2005 | US20050107345 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 05/19/2005 | US20050107340 Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease |
| 05/19/2005 | US20050107333 Use of mannosamine derivatives for the stimulation of neurite growth |